Related Experiment Videos
Heparin-induced thrombocytopenia: an overview
1Department of Medicine, McMaster University Medical Center, Hamilton, Ontario, Canada. keltonkg@mcmaster.ca
Blood Reviews
|March 27, 2002
Summary
Heparin-induced thrombocytopenia (HIT) is a serious immune drug reaction causing low platelets and blood clots. Understanding its pathophysiology guides the use of antithrombin agents for effective HIT treatment.
Area of Science:
- Immunology
- Hematology
- Pharmacology
Background:
- Heparin-induced thrombocytopenia (HIT) is a critical immunological drug reaction.
- HIT onset varies, typically occurring around 5 days after heparin initiation.
- It involves platelet activation leading to thrombocytopenia and thrombotic events.
Purpose of the Study:
- To elucidate the pathophysiology of Heparin-induced thrombocytopenia (HIT).
- To highlight the link between thrombocytopenia and thrombotic episodes in HIT.
- To discuss current therapeutic strategies for managing HIT.
Main Methods:
- Characterization of the immune mechanisms underlying HIT.
- Analysis of platelet activation pathways involving heparin and platelet factor 4 (PF4).
- Review of clinical data on HIT onset and associated thrombotic risks.
Main Results:
- HIT involves IgG-heparin immune complexes binding to Fc receptors on platelets.
- Platelet activation releases procoagulant microparticles, leading to thrombin generation.
- Thrombocytopenia and thrombosis are concurrent manifestations of the HIT syndrome.
Conclusions:
- HIT is an immune-mediated syndrome driven by platelet activation.
- Intense thrombin generation is a hallmark of HIT.
- Antithrombin agents are indicated for HIT therapy based on its pathophysiology.